Swiss Life Sciences Stock News

ABB (SWX:ABBN) is featured as a major supplier of synchronous condensers as global grid operators invest in equipment to support renewable energy integration. The company is highlighted for coupling these large rotating machines with digital monitoring and control tools for grid stability projects. Growing interest in grid modernization gives ABB additional visibility in a niche segment of transmission infrastructure. For you as an investor, this centers ABB around a key piece of hardware...

It looks like Bucher Industries AG ( VTX:BUCN ) is about to go ex-dividend in the next four days. The ex-dividend date...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see...

Nestlé S.A. ( VTX:NESN ) stock is about to trade ex-dividend in 4 days. The ex-dividend date is commonly two business...

Cosmo Pharmaceuticals N.V. reported that shareholders at its recent Ordinary AGM approved all proposals, including a €2.10 per share dividend, with the ex-dividend date set for 24 April 2026 and payment on 11 May 2026. This broad shareholder backing for both governance items and a cash distribution highlights confidence in the company’s capital allocation approach and cash-generating capacity. We’ll now examine how this newly approved €2.10 dividend and strong shareholder support feed into...

Burkhalter Holding (SWX:BRKN) has opened FY 2025 with first half revenue of CHF 559.0 million and basic EPS of CHF 2.26, providing a new set of figures for investors to compare with its recent track record. Over the past few reporting periods, revenue changed from CHF 526.9 million and EPS of CHF 2.19 in 1H 2024 to CHF 629.7 million and EPS of CHF 3.20 in 2H 2024. Trailing 12 month EPS was most recently CHF 5.78 on revenue of about CHF 1.2b, giving context to a business where profitability...

R&S Group Holding AG recently reported its full-year 2025 results, with sales rising to CHF 414.84 million and net income reaching CHF 58.1 million, both higher than the prior year. The improvement in basic earnings per share from continuing operations to CHF 1.56 highlights enhanced profitability on a per-share basis alongside the company’s broader growth. With this earnings-driven backdrop and stronger per-share profitability, we will explore how these results shape R&S Group Holding’s...

In early April 2026, Roche announced that its Elecsys Neurofilament Light Chain (NfL) blood test received CE mark approval for detecting neuroinflammation in adults with relapsing-remitting multiple sclerosis, enabling minimally invasive monitoring via its widely installed cobas instruments. This approval could materially change multiple sclerosis care pathways by shifting more frequent disease monitoring from hospital-based MRI scans to accessible, standardized blood testing. Next, we’ll...

Sensirion Holding (SWX:SENS) is back in focus after partnering with ClimeFi to secure durable carbon removal solutions through 2028. This reinforces its net zero roadmap while interest in its AI related sensor business stays in view. See our latest analysis for Sensirion Holding. The latest moves come against a backdrop of improving momentum, with a 1 month share price return of 10.65% and a 1 year total shareholder return of 11.42%, even though the 3 year total shareholder return is a 32.85%...

Romande Energie Holding SA's ( VTX:REHN ) solid earnings announcement recently didn't do much to the stock price. We...

Idorsia’s pediatric insomnia data puts daridorexant in the spotlight Idorsia (SWX:IDIA) is back on investors’ radar after reporting statistically significant, dose dependent improvements in sleep time for children with insomnia treated with daridorexant, confirming safety and efficacy in patients as young as ten. See our latest analysis for Idorsia. Despite the positive pediatric insomnia data and the recent leadership change in clinical development, Idorsia’s CHF3.524 share price reflects...

Earlier in April 2026, ams-OSRAM reported stronger-than-expected trading, underpinned by improving margins and increased orders for its optical sensor portfolio in automotive and AI applications. The news highlighted how renewed demand for AI-related optical sensors is starting to influence perceptions of ams-OSRAM’s operational progress despite ongoing balance sheet and profitability challenges. We’ll now examine how this renewed interest in AI-related optical sensors could shape...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

Sandoz Group shareholders approved all proposals at the 2026 AGM, including board re elections and governance roles. Compensation plans for leadership and a dividend payment were endorsed, confirming broad investor backing. The AGM outcome points to continuity in how Sandoz Group is run and how its strategy is overseen. Sandoz Group (SWX:SDZ) held this AGM with the share price at CHF66.62 and a 1 year return of 114.0%. The stock has also posted returns of 4.1% over the past week, 7.6% over...

SaltX recently reported that it has completed the first industrial-scale test period of electrified precalcination of Holcim’s cement raw meal at its ECRC facility in Hofors, Sweden, achieving positive calcination results and operational stability while processing around 20 tonnes per test run. This progress, alongside parallel work on electrified sintering and a fully electrified pilot plant targeted for 2028, highlights Holcim’s push to electrify and decarbonize cement production at an...

Earnings highlight and why it matters now R&S Group Holding (SWX:RSGN) just released its full year 2025 results, with sales of CHF 414.84 million, revenue of CHF 417.53 million, and net income of CHF 58.1 million drawing fresh attention to the stock. See our latest analysis for R&S Group Holding. The latest results appear to have kept momentum strong, with the share price at CHF24.2 and a 7 day share price return of 22.84% building on a 90 day share price return of 55.33%. The 3 year total...

Julius Bär Gruppe (SWX:BAER) is in the spotlight after a series of leadership changes, including the planned departure of finance chief Evie Kostakis and new board responsibilities for incoming non executive director Colin Bell. See our latest analysis for Julius Bär Gruppe. The executive reshuffle comes as the stock shows mixed momentum, with a 4.9% 1 month share price return and a 1 year total shareholder return of 33.7% contrasting with weaker recent quarterly performance. If leadership...

Medacta Group (SWX:MOVE) has stepped into an unusual spotlight after being selected to engineer a load bearing hip implant for a resurrected Tyrannosaurus rex as part of an international dinosaur revival project. See our latest analysis for Medacta Group. While the dinosaur project has put Medacta in the headlines, the CHF153.4 share price sits below its recent peak, with short term share price returns weaker. However, a 1 year total shareholder return of 34.52% still points to solid long...

Avolta (SWX:AVOL) has secured a 15 year food and beverage contract at Jacksonville International Airport in Florida, adding a new airport food hall with four outlets that mix local concepts and national brands. See our latest analysis for Avolta. The Jacksonville contract lands at a time when Avolta’s share price sits at CHF52.2, with a 1 month share price return of 8.70% and a 1 year total shareholder return of 57.10%. This suggests momentum has been building recently despite a weaker 5 year...

It looks like Geberit AG ( VTX:GEBN ) is about to go ex-dividend in the next four days. The ex-dividend date is...

How the Clareon TruPlus launch is feeding into Alcon’s stock story Alcon (SWX:ALC) is back in focus after the U.S. launch of its Clareon TruPlus intraocular lens at the ASCRS meeting, a move that helped spark a 3.96% share price gain. The new monofocal and toric lens expands Alcon’s cataract surgery lineup with extended depth of focus and lower glare. This comes alongside ongoing medical conference presentations that spotlight the product’s clinical profile and potential relevance for...

Galderma Group (SWX:GALD) is back in focus after new clinical data on Sculptra and Restylane in menopause and medication driven weight loss, fresh nemolizumab results in pediatric atopic dermatitis, and the ALASTIN Signature Practices rollout. See our latest analysis for Galderma Group. The latest clinical readouts and the ALASTIN Signature Practices launch come after a mixed year for the shares, with a 5.83% 1 month share price return, a 3.27% 3 month share price decline, and a 1 year total...

Mobimo Holding (SWX:MOBN) confirmed a total distribution of CHF 10.25 per registered share at its 31 March 2026 AGM and elected management consultant Sophie Dubuis to the Board of Directors, developments that shareholders are watching closely. See our latest analysis for Mobimo Holding. These AGM decisions come as the share price sits at CHF 381.0, with a 90 day share price return of 2.28% and a 1 year total shareholder return of 29.59% indicating momentum built more gradually over the longer...

Montana Aerospace (SWX:AERO) just posted its 2025 results, reporting higher sales from its Aerostructures segment along with a small net loss and a completed exit from its Energy business, which leaves it focused on aerospace. See our latest analysis for Montana Aerospace. The latest earnings release and Energy exit came after a weak period for the share price, with a 30 day share price return of an 18.01% decline and a 90 day share price return of a 25.08% decline. However, the 1 year total...